Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914719 | 0.98 | HCAR2 (0.45) | HCAR2ATMZDHHC7MAPTGPR84 | |
| SCHEMBL21694608 | 0.98 | HCAR2 (0.45) | HCAR2ATMZDHHC7MAPTGPR84 | |
| SCHEMBL18723218 | 0.98 | HCAR2 (0.45) | HCAR2ATMZDHHC7MAPTGPR84 | |
| SCHEMBL22627138 | 0.97 | HCAR2 (0.46) | HCAR2ATMZDHHC7MAPTCA2 | |
| SCHEMBL22465645 | 0.97 | HCAR2 (0.46) | HCAR2ATMZDHHC7MAPTCA2 | |
| SCHEMBL30914726 | 0.89 | ACHE (0.43) | HCAR2ATMZDHHC7MAPTCA2 | |
| SCHEMBL6476706 | 0.88 | TSHR (0.46) | HCAR2ATMMAPTCA2TSHR | |
| SCHEMBL6476703 | 0.88 | TSHR (0.46) | HCAR2ATMMAPTCA2TSHR | |
| SCHEMBL31578979 | 0.85 | ZDHHC7 (0.46) | HCAR2ZDHHC7MAPTCA2GPR84 | |
| SCHEMBL29001105 | 0.83 | TRPA1 (0.50) | HCAR2ATMMAPTGPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HCAR2 4309/4885ATM 2654/4885ZDHHC7 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.